{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:48:16Z","timestamp":1770140896018,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Comparative bioavailability studies often involve multiple groups of subjects for a variety of reasons, such as clinical capacity limitations. This raises questions about the validity of pooling data from these groups in the statistical analysis and whether a group-by-treatment interaction should be evaluated. We investigated the presence or absence of group-by-treatment interactions through both simulation techniques and a meta-study of well-controlled trials. Our findings reveal that the test falsely detects an interaction when no true group-by-treatment interaction exists. Conversely, when a true group-by-treatment interaction does exist, it often goes undetected. In our meta-study, the detected group-by-treatment interactions were observed at approximately the level of the test and, thus, can be considered false positives. Testing for a group-by-treatment interaction is both misleading and uninformative. It often falsely identifies an interaction when none exists and fails to detect a real one. This occurs because the test is performed between subjects in crossover designs, and studies are powered to compare treatments within subjects. This work demonstrates a lack of utility for including a group-by-treatment interaction in the model when assessing single-site comparative bioavailability studies, and the clinical trial study structure is divided into groups.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1208\/s12248-024-00921-x","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T20:19:51Z","timestamp":1713385191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies"],"prefix":"10.1208","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-7880","authenticated-orcid":false,"given":"Helmut","family":"Sch\u00fctz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8096-6371","authenticated-orcid":false,"given":"Divan A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-5602","authenticated-orcid":false,"given":"Erik","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3039-3808","authenticated-orcid":false,"given":"David D.","family":"Dubins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Fark\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-426X","authenticated-orcid":false,"given":"Detlew","family":"Labes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-5820","authenticated-orcid":false,"given":"Arne","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-7316","authenticated-orcid":false,"given":"Anastasia","family":"Shitova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volodymyr","family":"Stus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tomashevskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"921_CR1","unstructured":"US Food and Drug Administration, CDER. Guidance for industry. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Silver Spring, August 2021. https:\/\/www.fda.gov\/media\/87219\/download. Accessed 22 October 2023."},{"key":"921_CR2","unstructured":"Health Canada, Guidance Document. Conduct and analysis of comparative bioavailability studies. Ottawa. Revised Date: 2023\/01\/30. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/conduct-analysis-comparative.pdf. Accessed 22 October 2023."},{"issue":"4","key":"921_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1208\/s12248-013-9499-x","volume":"15","author":"B Davit","year":"2013","unstructured":"Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 2013;15(4):974\u2013290. https:\/\/doi.org\/10.1208\/s12248-013-9499-x.","journal-title":"AAPS J"},{"key":"921_CR4","unstructured":"EMA, CHMP. Guideline on the investigation of bioequivalence. London; 2010. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 22 October 2023."},{"key":"921_CR5","unstructured":"ICH. Bioequivalence for immediate release solid oral dosage forms. M13A. Draft version. 20 December 2022. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M13A_Step2_draft_Guideline_2022_1125.pdf. Accessed 22 October 2023."},{"key":"921_CR6","unstructured":"US Food and Drug Administration, CDER. Guidance for industry. Bioavailability studies submitted in NDAs or INDs \u2014 general considerations. Silver Spring, April 2022. https:\/\/www.fda.gov\/media\/121311\/download. Accessed 22 October 2023."},{"key":"921_CR7","unstructured":"US Food and Drug Administration, CDER. Guidance for industry. SUPAC-IR: immediate-release solid oral dosage forms: scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. Rockville, November 1995. https:\/\/www.fda.gov\/media\/70949\/download. Accessed 22 October 2023."},{"key":"921_CR8","unstructured":"US Food and Drug Administration, CDER. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. Rockville, December 2002. https:\/\/www.fda.gov\/files\/drugs\/published\/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf. Accessed 22 October 2023."},{"key":"921_CR9","unstructured":"US Food and Drug Administration, CDER. Guidance for industry. Clinical drug interaction studies \u2014 cytochrome P450 enzyme- and transporter-mediated drug interactions. Silver Spring, January 2020. https:\/\/www.fda.gov\/media\/134581\/download. Accessed 22 October 2023."},{"key":"921_CR10","unstructured":"European Medicines Agency, CHMP. Guideline on the investigation of drug interactions. Revision 1. London, 21 June 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 22 October 2023."},{"key":"921_CR11","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria, 2023. https:\/\/www.r-project.org\/.\u00a0Accessed 22 Oct 2023."},{"key":"921_CR12","unstructured":"US Food and Drug Administration, CDER. ANDA 077570. Bioequivalence reviews. 2008. Control document #98\u2013392 regarding the Group-by-Treatment interaction discussion. Rockville, September 10, 1999. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/anda\/2008\/077570Orig1s000BioeqR.pdf. Accessed 22 October 2023."},{"key":"921_CR13","first-page":"629","volume-title":"Pharmaceutical statistics. Practical and clinical applications","author":"S Bolton","year":"2010","unstructured":"Bolton S, Bon C. Pharmaceutical statistics. Practical and clinical applications. 5th ed. New York: Informa Healthcare; 2010. p. 629.","edition":"5"},{"key":"921_CR14","unstructured":"US Food and Drug Administration, CDER. Guidance for industry. Statistical approaches to establishing bioequivalence. Revision 1. Silver Spring, December 2022. https:\/\/www.fda.gov\/media\/163638\/download. Accessed 22 October 2023."},{"key":"921_CR15","unstructured":"Sun W. Bioequivalence studies in multiple groups. Presentation at: SBIA. A deep dive: FDA draft guidance on statistical approaches to establishing bioequivalence. Silver Spring, March 14, 2023. https:\/\/www.fda.gov\/media\/167459\/download. Accessed 22 October 2023."},{"key":"921_CR16","unstructured":"Council of the Eurasian Economic Community. On the approval of the rules for conducting research of bioequivalence of drugs within the framework of the Eurasian Economic Union. November 3, 2016; amended September 4, 2020."},{"key":"921_CR17","first-page":"192","volume-title":"Principles and perspectives in drug bioavailability","author":"WJ Westlake","year":"1979","unstructured":"Westlake WJ. Design and evaluation of bioequivalence studies in man. In: Blanchard J, Sawchuk RJ, Brodie BB, editors. Principles and perspectives in drug bioavailability. Basel: Karger; 1979. p. 192\u2013210."},{"key":"921_CR18","first-page":"336","volume-title":"Biopharmaceutical statistics for drug development","author":"WJ Westlake","year":"1988","unstructured":"Westlake WJ. Bioavailability and bioequivalence of pharmaceutical formulations. In: Peace KE, editor. Biopharmaceutical statistics for drug development. New York: Marcel Dekker; 1988. p. 336\u20137."},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/pst.1522","volume":"11","author":"C Zheng","year":"2012","unstructured":"Zheng C, Wang J, Zhao L. Testing bioequivalence for multiple formulations with power and sample size calculations. Pharm Stat. 2012;11:334\u201341. https:\/\/doi.org\/10.1002\/pst.1522.","journal-title":"Pharm Stat"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1145\/272991.272995","volume":"8","author":"M Matsumoto","year":"1998","unstructured":"Matsumoto M, Nishimura T. Mersenne twister: a 623-dimensionally equidistributed uniform pseudo-random number generator. ACM Trans Model Comput Simul. 1998;8:3\u201330. https:\/\/doi.org\/10.1145\/272991.272995.","journal-title":"ACM Trans Model Comput Simul"},{"key":"921_CR21","unstructured":"Medicines for Europe. Second bioequivalence workshop. Session 2 \u2013 ICH M13 \u2013 bioequivalence for IR solid oral dosage forms. Brussels; 2023."},{"key":"921_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2022.2123385","author":"W Sun","year":"2022","unstructured":"Sun W, Schuirmann D, Grosser S. Qualitative versus quantitative treatment-by-subgroup interaction in equivalence studies with multiple subgroups. Stat Biopharm Res. 2022. https:\/\/doi.org\/10.1080\/19466315.2022.2123385.","journal-title":"Stat Biopharm Res"},{"issue":"1&2","key":"921_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1081\/bip-100104196","volume":"11","author":"G D\u2019Angelo","year":"2001","unstructured":"D\u2019Angelo G, Potvin D, Turgeon J. Carry-over effects in bioequivalence studies. J Biopharm Stat. 2001;11(1&2):35\u201343. https:\/\/doi.org\/10.1081\/bip-100104196.","journal-title":"J Biopharm Stat"},{"issue":"1","key":"921_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1348\/000711004849222","volume":"57","author":"DW Zimmerman","year":"2004","unstructured":"Zimmerman DW. A note on preliminary tests of equality of variances. Br J Math Stat Psychol. 2004;57(1):173\u201381. https:\/\/doi.org\/10.1348\/000711004849222.","journal-title":"Br J Math Stat Psychol"},{"issue":"12","key":"921_CR25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/sim.4780081202","volume":"8","author":"PR Freeman","year":"1989","unstructured":"Freeman PR. The performance of the two-stage analysis of two-treatment, two-period crossover trials. Statist Med. 1989;8(12):1421\u201332. https:\/\/doi.org\/10.1002\/sim.4780081202.","journal-title":"Statist Med"},{"key":"921_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/pst.111","volume":"3","author":"S Senn","year":"2004","unstructured":"Senn S, D\u2019Angelo G, Potvin D. Carry-over in cross-over trials in bioequivalence: theoretical concerns and empirical evidence. Pharm Stat. 2004;3:133\u201342. https:\/\/doi.org\/10.1002\/pst.111.","journal-title":"Pharm Stat"},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/1097-0258(20001030)19:20<2867::AID-SIM551>3.0.CO;2-J","volume":"19","author":"L Endr\u00e9nyi","year":"2000","unstructured":"Endr\u00e9nyi L, Taback N, T\u00f3thfalusi. Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence. Statist Med. 2000;19:2867\u201378. https:\/\/doi.org\/10.1002\/1097-0258(20001030)19:20%3C2867::aid-sim551%3E3.0.co;2-j.","journal-title":"Statist Med."},{"key":"921_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/pst.294","volume":"7","author":"D Potvin","year":"2008","unstructured":"Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA. Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat. 2008;7:245\u201362. https:\/\/doi.org\/10.1002\/pst.294.","journal-title":"Pharm Stat"},{"key":"921_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pst.483","volume":"11","author":"TH Montague","year":"2011","unstructured":"Montague TH, Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ. Additional results for \u2018Sequential design approaches for bioequivalence studies with crossover designs.\u2019 Pharm Stat. 2011;11:8\u201313. https:\/\/doi.org\/10.1002\/pst.483.","journal-title":"Pharm Stat."},{"key":"921_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1208\/s12248-013-9475-5","volume":"15","author":"A Fuglsang","year":"2013","unstructured":"Fuglsang A. Sequential bioequivalence trial designs with increased power and controlled type I error rates. AAPS J. 2013;15:659\u201361. https:\/\/doi.org\/10.1208\/s12248-013-9475-5.","journal-title":"AAPS J"},{"key":"921_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1208\/s12248-014-9571-1","volume":"16","author":"A Fuglsang","year":"2014","unstructured":"Fuglsang A. Sequential bioequivalence approaches for parallel designs. AAPS J. 2014;16:373\u20138. https:\/\/doi.org\/10.1208\/s12248-014-9571-1.","journal-title":"AAPS J"},{"issue":"10","key":"921_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/sim.7614","volume":"37","author":"W Maurer","year":"2018","unstructured":"Maurer W, Jones B, Chen Y. Controlling the type 1 error rate in two-stage sequential designs when testing for average bioequivalence. Statist Med. 2018;37(10):1\u201321. https:\/\/doi.org\/10.1002\/sim.7614.","journal-title":"Statist Med"},{"issue":"1","key":"921_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cpt.2050","volume":"110","author":"J Lee","year":"2020","unstructured":"Lee J, Feng K, Xu M, Gong X, Sun W, Kim J, Zhang Z, Wang M, Fang L, Zhao L. Applications of adaptive designs in generic drug development. Clin Pharm Ther. 2020;110(1):32\u20135. https:\/\/doi.org\/10.1002\/cpt.2050.","journal-title":"Clin Pharm Ther"},{"issue":"1","key":"921_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/bimj.201900388","volume":"63","author":"E Molins","year":"2021","unstructured":"Molins E, Labes D, Sch\u00fctz H, Cobo E, Oca\u00f1a J. An iterative method to protect the type I error rate in bioequivalence studies under two-stage adaptive 2\u00d72 crossover designs. Biom J. 2021;63(1):122\u201333. https:\/\/doi.org\/10.1002\/bimj.201900388.","journal-title":"Biom J"},{"issue":"1","key":"921_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7326\/M18-3667","volume":"172","author":"DM Kent","year":"2020","unstructured":"Kent DM, Paulus JK, van Klaveren D, D\u2019Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HS, Varadhan R, Vickers A, Wong JB, Steyerberg EW. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med. 2020;172(1):35\u201345. https:\/\/doi.org\/10.7326\/M18-3667.","journal-title":"Ann Intern Med"},{"issue":"4","key":"921_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/19466315.2015.1077726","volume":"7","author":"M Alosh","year":"2015","unstructured":"Alosh M, Fritsch K, Huque M, Mahjoob K, Pennello G, Rothmann M, Russek-Cohen E, Smith F, Wilson S, Yue L. Statistical considerations on subgroup analysis in clinical trials. Stat Biopharm Res. 2015;7(4):286\u2013304. https:\/\/doi.org\/10.1080\/19466315.2015.1077726.","journal-title":"Stat Biopharm Res"},{"key":"921_CR37","first-page":"603","volume-title":"Numerical recipes in Fortran 77: the art of scientific computing","author":"WH Press","year":"1992","unstructured":"Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes in Fortran 77: the art of scientific computing. 2nd ed. Cambridge: Cambridge University Press; 1992. p. 603.","edition":"2"},{"issue":"2","key":"921_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA\u2019s statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129\u201333. https:\/\/doi.org\/10.1080\/00031305.2016.1154108.","journal-title":"Am Stat"},{"issue":"3","key":"921_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1198\/0003130031856","volume":"57","author":"R Hubbard","year":"2003","unstructured":"Hubbard R, Bayarri MJ. Confusion over measures of evidence (p\u2019s) versus errors (\u03b1\u2019s) in classical statistical testing. Am Stat. 2003;57(3):171\u201382. https:\/\/doi.org\/10.1198\/0003130031856.","journal-title":"Am Stat"},{"key":"921_CR40","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s J, Casals M, Langohr K, Gonz\u00e1lez JA. Importance of statistical power and hypothesis in P value. Med Clin (Barc). 2016. https:\/\/doi.org\/10.1016\/j.medcli.2015.10.011.","DOI":"10.1016\/j.medcli.2015.10.011"}],"updated-by":[{"DOI":"10.1208\/s12248-024-00927-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000}}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00921-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-024-00921-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00921-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:12:15Z","timestamp":1721823135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-024-00921-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1208\/s12248-024-00921-x","relation":{"correction":[{"id-type":"doi","id":"10.1208\/s12248-024-00927-5","asserted-by":"object"}]},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1208\/s12248-024-00927-5","URL":"https:\/\/doi.org\/10.1208\/s12248-024-00927-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"50"}}